TIDMHCM

RNS Number : 2369B

Hutchison China Meditech Limited

15 June 2016

Block Admission

London: Wednesday, June 15, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that an application has been made to the London Stock Exchange plc for a block admission of 1,000,000 ordinary shares, par value of US$1.00 each ("Ordinary Shares") to be admitted to trading on AIM. It is expected that such admission will become effective on June 20, 2016.

These Ordinary Shares will be issued from time to time pursuant to the exercise of share options under the Share Option Scheme adopted by Chi-Med on May 13, 2016. When issued, these Ordinary Shares will be credited as fully paid and will rank pari passu with the existing Ordinary Shares in issue.

NOTES TO EDITORS

About Chi-Med

Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform, Hutchison MediPharma Limited, is focused on discovering, developing and commercializing innovative therapeutics in oncology and autoimmune diseases. Its pipeline of eight novel oral compounds for cancer and inflammation is in development in North America, Europe, Australia and Greater China.

Chi-Med's Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.

Contacts

 
Investor Enquiries 
Christian Hogg, CEO                        +852 2121 8200 
 
International Media Enquiries 
Anthony Carlisle, Citigate Dewe Rogerson   +44 7973 611 888 (Mobile)   anthony.carlisle@cdrconsultancy.co.uk 
 
U.S. Based Media Enquiries 
Brad Miles, BMC Communications             +1 (917) 570 7340 (Mobile)  bmiles@bmccommunications.com 
Susan Duffy, BMC Communications            +1 (917) 499 8887 (Mobile)  sduffy@bmccommunications.com 
 
Investor Relations 
Jillian Connell, The Trout Group           +1 (646) 378 2956           jconnell@troutgroup.com 
David Dible, Citigate Dewe Rogerson        +44 7967 566 919 (Mobile)   david.dible@citigatedr.co.uk 
 
Panmure Gordon (UK) Limited 
Richard Gray / Andrew Potts                +44 (20) 7886 2500 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

ALSGGUWUQUPQUMA

(END) Dow Jones Newswires

June 15, 2016 03:09 ET (07:09 GMT)